NO313785B1 - Flutikason-propionatformuleringer, fremgangsmÕte for fremstilling derav, beholder som omfatter formuleringene, samtanvendelse av formuleringene - Google Patents
Flutikason-propionatformuleringer, fremgangsmÕte for fremstilling derav, beholder som omfatter formuleringene, samtanvendelse av formuleringene Download PDFInfo
- Publication number
- NO313785B1 NO313785B1 NO19964938A NO964938A NO313785B1 NO 313785 B1 NO313785 B1 NO 313785B1 NO 19964938 A NO19964938 A NO 19964938A NO 964938 A NO964938 A NO 964938A NO 313785 B1 NO313785 B1 NO 313785B1
- Authority
- NO
- Norway
- Prior art keywords
- formulation
- formulation according
- sorbitan monolaurate
- polyoxyethylene
- fluticasone propionate
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 69
- 238000009472 formulation Methods 0.000 title claims abstract description 68
- 229960000289 fluticasone propionate Drugs 0.000 title claims abstract description 26
- WMWTYOKRWGGJOA-CENSZEJFSA-N fluticasone propionate Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(OC(=O)CC)[C@@]2(C)C[C@@H]1O WMWTYOKRWGGJOA-CENSZEJFSA-N 0.000 title claims abstract description 26
- 238000000034 method Methods 0.000 title abstract description 8
- 238000002360 preparation method Methods 0.000 title description 2
- 239000004094 surface-active agent Substances 0.000 claims abstract description 15
- 239000002245 particle Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 238000002663 nebulization Methods 0.000 claims abstract description 6
- 208000006673 asthma Diseases 0.000 claims abstract description 4
- 239000003795 chemical substances by application Substances 0.000 claims abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 16
- 229920001213 Polysorbate 20 Polymers 0.000 claims description 13
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 claims description 13
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 claims description 12
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 12
- 229940035044 sorbitan monolaurate Drugs 0.000 claims description 12
- 239000000725 suspension Substances 0.000 claims description 10
- 239000011780 sodium chloride Substances 0.000 claims description 8
- VBJGJHBYWREJQD-UHFFFAOYSA-M sodium;dihydrogen phosphate;dihydrate Chemical compound O.O.[Na+].OP(O)([O-])=O VBJGJHBYWREJQD-UHFFFAOYSA-M 0.000 claims description 7
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 239000004615 ingredient Substances 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 239000006199 nebulizer Substances 0.000 claims description 4
- -1 polyoxyethylene Polymers 0.000 claims description 4
- ARIWANIATODDMH-UHFFFAOYSA-N rac-1-monolauroylglycerol Chemical compound CCCCCCCCCCCC(=O)OCC(O)CO ARIWANIATODDMH-UHFFFAOYSA-N 0.000 claims description 4
- 239000007787 solid Substances 0.000 claims description 4
- 210000004072 lung Anatomy 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 claims description 2
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 2
- HJRDNARELSKHEF-CLFAGFIQSA-N 2-[2-[(z)-octadec-9-enoyl]oxyethoxy]ethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCCOCCOC(=O)CCCCCCC\C=C/CCCCCCCC HJRDNARELSKHEF-CLFAGFIQSA-N 0.000 claims description 2
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 2
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 claims description 2
- GOOHAUXETOMSMM-UHFFFAOYSA-N Propylene oxide Chemical group CC1CO1 GOOHAUXETOMSMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000004147 Sorbitan trioleate Substances 0.000 claims description 2
- PRXRUNOAOLTIEF-ADSICKODSA-N Sorbitan trioleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)[C@H]1OC[C@H](O)[C@H]1OC(=O)CCCCCCC\C=C/CCCCCCCC PRXRUNOAOLTIEF-ADSICKODSA-N 0.000 claims description 2
- 229920001400 block copolymer Polymers 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 claims description 2
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 claims description 2
- 229940093471 ethyl oleate Drugs 0.000 claims description 2
- 229940068939 glyceryl monolaurate Drugs 0.000 claims description 2
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 2
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 2
- GIPDEPRRXIBGNF-KTKRTIGZSA-N oxolan-2-ylmethyl (z)-octadec-9-enoate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC1CCCO1 GIPDEPRRXIBGNF-KTKRTIGZSA-N 0.000 claims description 2
- 125000006353 oxyethylene group Chemical group 0.000 claims description 2
- 229940068918 polyethylene glycol 400 Drugs 0.000 claims description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 claims description 2
- 239000001593 sorbitan monooleate Substances 0.000 claims description 2
- 229940035049 sorbitan monooleate Drugs 0.000 claims description 2
- 235000019337 sorbitan trioleate Nutrition 0.000 claims description 2
- 229960000391 sorbitan trioleate Drugs 0.000 claims description 2
- 229940072958 tetrahydrofurfuryl oleate Drugs 0.000 claims description 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 239000000872 buffer Substances 0.000 abstract description 5
- 238000000889 atomisation Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000000241 respiratory effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000007906 compression Methods 0.000 description 2
- 230000006835 compression Effects 0.000 description 2
- 239000010419 fine particle Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 1
- 229940075564 anhydrous dibasic sodium phosphate Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002178 crystalline material Substances 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- MGNNYOODZCAHBA-GQKYHHCASA-N fluticasone Chemical class C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@@H](C)[C@@](C(=O)SCF)(O)[C@@]2(C)C[C@@H]1O MGNNYOODZCAHBA-GQKYHHCASA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000704 physical effect Effects 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 229940068977 polysorbate 20 Drugs 0.000 description 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9410222A GB9410222D0 (en) | 1994-05-21 | 1994-05-21 | Medicaments |
| PCT/EP1995/001913 WO1995031964A1 (en) | 1994-05-21 | 1995-05-19 | Fluticasone propionate formulations |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO964938D0 NO964938D0 (no) | 1996-11-20 |
| NO964938L NO964938L (no) | 1996-11-20 |
| NO313785B1 true NO313785B1 (no) | 2002-12-02 |
Family
ID=10755515
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19964938A NO313785B1 (no) | 1994-05-21 | 1996-11-20 | Flutikason-propionatformuleringer, fremgangsmÕte for fremstilling derav, beholder som omfatter formuleringene, samtanvendelse av formuleringene |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US5993781A (sv) |
| EP (1) | EP0760649B1 (sv) |
| JP (1) | JPH10500420A (sv) |
| KR (2) | KR100361413B1 (sv) |
| CN (1) | CN1098680C (sv) |
| AT (1) | ATE207734T1 (sv) |
| AU (1) | AU710821B2 (sv) |
| BR (1) | BR9507746A (sv) |
| CA (1) | CA2190763A1 (sv) |
| CY (1) | CY2294B1 (sv) |
| CZ (1) | CZ285966B6 (sv) |
| DE (1) | DE69523587T2 (sv) |
| DK (1) | DK0760649T3 (sv) |
| ES (1) | ES2164767T3 (sv) |
| FI (1) | FI118512B (sv) |
| GB (1) | GB9410222D0 (sv) |
| HK (1) | HK1004192A1 (sv) |
| HU (1) | HU223316B1 (sv) |
| IL (1) | IL113794A (sv) |
| MX (1) | MX9605650A (sv) |
| NO (1) | NO313785B1 (sv) |
| NZ (1) | NZ287425A (sv) |
| PL (1) | PL180318B1 (sv) |
| PT (1) | PT760649E (sv) |
| RU (1) | RU2161485C2 (sv) |
| SI (1) | SI0760649T1 (sv) |
| TW (1) | TW438604B (sv) |
| WO (1) | WO1995031964A1 (sv) |
| ZA (1) | ZA954101B (sv) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU4990696A (en) * | 1995-02-24 | 1996-09-11 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
| GB9610341D0 (en) * | 1996-05-17 | 1996-07-24 | Andaris Ltd | Formulation for inhalation |
| US20060165606A1 (en) | 1997-09-29 | 2006-07-27 | Nektar Therapeutics | Pulmonary delivery particles comprising water insoluble or crystalline active agents |
| SE9704186D0 (sv) | 1997-11-14 | 1997-11-14 | Astra Ab | New composition of matter |
| US6241969B1 (en) * | 1998-06-26 | 2001-06-05 | Elan Corporation Plc | Aqueous compositions containing corticosteroids for nasal and pulmonary delivery |
| US8820316B2 (en) * | 2000-02-11 | 2014-09-02 | Respironics Respiratory Drug Delivery (Uk) Ltd | Drug delivery apparatus |
| US7871598B1 (en) | 2000-05-10 | 2011-01-18 | Novartis Ag | Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use |
| US6858596B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivative |
| US6777400B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| US6759398B2 (en) | 2000-08-05 | 2004-07-06 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative |
| US6858593B2 (en) | 2000-08-05 | 2005-02-22 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| GB0019172D0 (en) | 2000-08-05 | 2000-09-27 | Glaxo Group Ltd | Novel compounds |
| US6787532B2 (en) * | 2000-08-05 | 2004-09-07 | Smithkline Beecham Corporation | Formulation containing anti-inflammatory androstane derivatives |
| US6750210B2 (en) | 2000-08-05 | 2004-06-15 | Smithkline Beecham Corporation | Formulation containing novel anti-inflammatory androstane derivative |
| US6777399B2 (en) | 2000-08-05 | 2004-08-17 | Smithkline Beecham Corporation | Anti-inflammatory androstane derivative compositions |
| UA77656C2 (en) | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
| US6667344B2 (en) | 2001-04-17 | 2003-12-23 | Dey, L.P. | Bronchodilating compositions and methods |
| US20030055026A1 (en) | 2001-04-17 | 2003-03-20 | Dey L.P. | Formoterol/steroid bronchodilating compositions and methods of use thereof |
| US7368102B2 (en) | 2001-12-19 | 2008-05-06 | Nektar Therapeutics | Pulmonary delivery of aminoglycosides |
| CA2475092C (en) | 2002-02-04 | 2012-05-01 | Christian F. Wertz | Nanoparticulate compositions having lysozyme as a surface stabilizer |
| SI1476201T1 (sl) | 2002-02-19 | 2009-06-30 | Resolution Chemicals Ltd | Sterilizacija steroidov, osnovana na topilu |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| JP2006501936A (ja) * | 2002-10-04 | 2006-01-19 | エラン ファーマ インターナショナル，リミティド | 固体ナノ粒子活性薬剤のガンマ線照射 |
| US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
| EP1454636A1 (en) * | 2003-03-04 | 2004-09-08 | Dompé S.P.A. | Sterilization of glucocorticoid drug particles for pulmonary delivery |
| US7811606B2 (en) * | 2003-04-16 | 2010-10-12 | Dey, L.P. | Nasal pharmaceutical formulations and methods of using the same |
| US8912174B2 (en) * | 2003-04-16 | 2014-12-16 | Mylan Pharmaceuticals Inc. | Formulations and methods for treating rhinosinusitis |
| US9808471B2 (en) | 2003-04-16 | 2017-11-07 | Mylan Specialty Lp | Nasal pharmaceutical formulations and methods of using the same |
| CA2523035C (en) * | 2003-05-22 | 2011-04-26 | Elan Pharma International Ltd. | Sterilization of dispersions of nanoparticulate active agents with gamma radiation |
| US20040265238A1 (en) * | 2003-06-27 | 2004-12-30 | Imtiaz Chaudry | Inhalable formulations for treating pulmonary hypertension and methods of using same |
| TWI359675B (en) | 2003-07-10 | 2012-03-11 | Dey L P | Bronchodilating β-agonist compositions |
| DE10347994A1 (de) | 2003-10-15 | 2005-06-16 | Pari GmbH Spezialisten für effektive Inhalation | Wässrige Aerosol-Zubereitung |
| PE20050941A1 (es) | 2003-12-16 | 2005-11-08 | Nycomed Gmbh | Suspensiones acuosas de ciclesonida para nebulizacion |
| US7892483B2 (en) | 2004-03-12 | 2011-02-22 | Cipla Limited | Sterilization process |
| GB0410995D0 (en) * | 2004-05-17 | 2004-06-23 | Norton Healthcare Ltd | Heat sterilization of glucocorticosteroids |
| GB0425266D0 (en) * | 2004-11-16 | 2004-12-15 | Norton Healthcare Ltd | Pharmaceutical manufacturing process |
| GB0427568D0 (en) * | 2004-12-16 | 2005-01-19 | Resolution Chemicals Ltd | Particle-size reduction apparatus, and the use thereof |
| US20090311335A1 (en) * | 2008-06-12 | 2009-12-17 | Scott Jenkins | Combination of a triptan and an nsaid |
| CN102166219B (zh) * | 2010-05-25 | 2013-04-17 | 杭州天龙药业有限公司 | 一种鼻腔给药制剂及其应用 |
| US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| MX361886B (es) | 2012-05-08 | 2018-12-18 | Nicox Ophthalmics Inc | Preparaciones de agentes terapéuticos hidrófobos, métodos de elaboración y uso de los mismos. |
| CN103505412A (zh) * | 2012-06-26 | 2014-01-15 | 上海臣邦医药科技有限公司 | 一种吸入用丙酸氟替卡松混悬液的制备方法 |
| WO2014007772A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions comprising glucose anhydrous |
| US10105316B2 (en) | 2012-07-05 | 2018-10-23 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising muscarinic receptor antagonist |
| US20150165037A1 (en) | 2012-07-05 | 2015-06-18 | Arven llac Sanayi Ve Ticaret A.S. | Inhalation compositions comprising corticosteroid and sorbitol |
| WO2014007781A2 (en) | 2012-07-05 | 2014-01-09 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Inhalation compositions |
| DE102012111077A1 (de) * | 2012-11-16 | 2014-05-22 | Justus-Liebig-Universität Giessen | Optimierung von Vernebelungseigenschaften einer Lösung oder eines Kolloids |
| US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
| SI3193835T1 (en) | 2014-09-15 | 2018-06-29 | Verona Pharma PLC Bradley Court | Liquid inhalation preparation containing rpl554 |
| US11756656B2 (en) | 2018-06-14 | 2023-09-12 | Astrazeneca Uk Limited | Methods for treating and preventing symptoms of asthma with a corticosteroid pharmaceutical composition |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5225183A (en) * | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| US5118494A (en) * | 1990-03-23 | 1992-06-02 | Minnesota Mining And Manufacturing Company | Use of soluble fluorosurfactants for the preparation of metered-dose aerosol formulations |
| US5658549A (en) * | 1991-12-12 | 1997-08-19 | Glaxo Group Limited | Aerosol formulations containing propellant 134a and fluticasone propionate |
| EP0616525B1 (en) * | 1991-12-12 | 1995-09-27 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
| HU227519B1 (en) * | 1991-12-18 | 2011-07-28 | Astra Ab | Synergic pharmaceutical composition containing combination of formoterol and budesonide |
| US5301664A (en) * | 1992-03-06 | 1994-04-12 | Sievers Robert E | Methods and apparatus for drug delivery using supercritical solutions |
| GB9419536D0 (en) * | 1994-09-28 | 1994-11-16 | Glaxo Inc | Medicaments |
-
1994
- 1994-05-21 GB GB9410222A patent/GB9410222D0/en active Pending
-
1995
- 1995-05-19 PL PL95317225A patent/PL180318B1/pl unknown
- 1995-05-19 WO PCT/EP1995/001913 patent/WO1995031964A1/en active IP Right Grant
- 1995-05-19 NZ NZ287425A patent/NZ287425A/en not_active IP Right Cessation
- 1995-05-19 RU RU96124389/14A patent/RU2161485C2/ru active
- 1995-05-19 JP JP7530051A patent/JPH10500420A/ja active Pending
- 1995-05-19 IL IL11379495A patent/IL113794A/xx not_active IP Right Cessation
- 1995-05-19 MX MX9605650A patent/MX9605650A/es unknown
- 1995-05-19 US US08/737,592 patent/US5993781A/en not_active Expired - Lifetime
- 1995-05-19 HU HU9603227A patent/HU223316B1/hu active IP Right Grant
- 1995-05-19 AU AU26145/95A patent/AU710821B2/en not_active Expired
- 1995-05-19 AT AT95920841T patent/ATE207734T1/de active
- 1995-05-19 DK DK95920841T patent/DK0760649T3/da active
- 1995-05-19 PT PT95920841T patent/PT760649E/pt unknown
- 1995-05-19 SI SI9530550T patent/SI0760649T1/xx unknown
- 1995-05-19 EP EP95920841A patent/EP0760649B1/en not_active Expired - Lifetime
- 1995-05-19 KR KR1019960706578A patent/KR100361413B1/ko not_active IP Right Cessation
- 1995-05-19 CN CN95193201A patent/CN1098680C/zh not_active Expired - Lifetime
- 1995-05-19 BR BR9507746A patent/BR9507746A/pt not_active IP Right Cessation
- 1995-05-19 CZ CZ963423A patent/CZ285966B6/cs not_active IP Right Cessation
- 1995-05-19 KR KR1019960706549A patent/KR970703132A/ko not_active Application Discontinuation
- 1995-05-19 DE DE69523587T patent/DE69523587T2/de not_active Expired - Lifetime
- 1995-05-19 ZA ZA954101A patent/ZA954101B/xx unknown
- 1995-05-19 CA CA002190763A patent/CA2190763A1/en not_active Abandoned
- 1995-05-19 ES ES95920841T patent/ES2164767T3/es not_active Expired - Lifetime
- 1995-06-17 TW TW084106242A patent/TW438604B/zh not_active IP Right Cessation
-
1996
- 1996-11-20 NO NO19964938A patent/NO313785B1/no not_active IP Right Cessation
- 1996-11-20 FI FI964634A patent/FI118512B/sv not_active IP Right Cessation
-
1998
- 1998-04-27 HK HK98103532A patent/HK1004192A1/xx not_active IP Right Cessation
-
2002
- 2002-09-02 CY CY0200053A patent/CY2294B1/xx unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO313785B1 (no) | Flutikason-propionatformuleringer, fremgangsmÕte for fremstilling derav, beholder som omfatter formuleringene, samtanvendelse av formuleringene | |
| KR20010042531A (ko) | 랄록시펜의 폐 및 경비 전달 | |
| EA012388B1 (ru) | Водные суспензии циклесонида для аэрозольного распыления | |
| US6187765B1 (en) | Mometasone furoate suspensions for nebulization | |
| EP1033991B1 (en) | Mometasone furoate suspensions for nebulization | |
| MX2013004030A (es) | Composicion farmaceutica a base de denufosol para tratar fibrosis quistica. | |
| EP1198224B1 (en) | Formulations of steroid solutions for inhalatory administration | |
| DK2704724T3 (en) | Improved suspension formulation of beclomethasone dipropionate for administration by inhalation | |
| WO2020220855A1 (zh) | 一种雾化吸入剂及其制备方法 | |
| CN117205186B (zh) | 一种雷芬那辛吸入喷雾剂及其制备方法 | |
| Khale et al. | Liposomal Nebulising Solutions of Salbutamol Sulphate-A Characterisation Study. | |
| CN114515279A (zh) | 一种安立生坦雾化吸入溶液及其制备方法 | |
| WO2021262648A1 (en) | Preparation of a pharmaceutical composition of olodaterol and budesonide | |
| CN114073684A (zh) | 三苯乙酸维兰特罗吸入溶液及其制备方法 | |
| US20040039020A1 (en) | Novel pharmaceutical formulation suitable for nebulisation | |
| MXPA00009704A (en) | Pulmonary and nasal delivery of raloxifene | |
| CZ20003544A3 (cs) | Pulmonární a nasální podávání raloxifenu | |
| MXPA00003476A (en) | Mometasone furoate suspensions for nebulization |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |